X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES FDC LTD. VENUS REMEDIES/
FDC LTD.
 
P/E (TTM) x -4.4 22.2 - View Chart
P/BV x 0.2 5.0 3.3% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   FDC LTD.
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
FDC LTD.
Mar-14
VENUS REMEDIES/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs126144 87.7%   
Low Rs6179 77.3%   
Sales per share (Unadj.) Rs301.847.6 634.5%  
Earnings per share (Unadj.) Rs-24.97.6 -326.8%  
Cash flow per share (Unadj.) Rs2.59.0 28.2%  
Dividends per share (Unadj.) Rs02.25 0.0%  
Dividend yield (eoy) %02.0 0.0%  
Book value per share (Unadj.) Rs293.347.5 617.0%  
Shares outstanding (eoy) m12.34177.83 6.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.32.3 13.2%   
Avg P/E ratio x-3.814.6 -25.7%  
P/CF ratio (eoy) x36.712.3 297.6%  
Price / Book Value ratio x0.32.3 13.6%  
Dividend payout %029.6 0.0%   
Avg Mkt Cap Rs m1,15419,784 5.8%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3931,221 32.2%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,7248,459 44.0%  
Other income Rs m23394 5.7%   
Total revenues Rs m3,7478,852 42.3%   
Gross profit Rs m3952,070 19.1%  
Depreciation Rs m338249 135.8%   
Interest Rs m35431 1,142.5%   
Profit before tax Rs m-2752,184 -12.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32606 5.2%   
Profit after tax Rs m-3071,353 -22.7%  
Gross profit margin %10.624.5 43.3%  
Effective tax rate %-11.527.7 -41.4%   
Net profit margin %-8.216.0 -51.5%  
BALANCE SHEET DATA
Current assets Rs m2,6384,355 60.6%   
Current liabilities Rs m2,3051,792 128.6%   
Net working cap to sales %8.930.3 29.5%  
Current ratio x1.12.4 47.1%  
Inventory Days Days13544 304.7%  
Debtors Days Days4625 187.8%  
Net fixed assets Rs m4,8713,025 161.0%   
Share capital Rs m123179 69.1%   
"Free" reserves Rs m3,4968,243 42.4%   
Net worth Rs m3,6198,453 42.8%   
Long term debt Rs m1,37411 12,844.9%   
Total assets Rs m7,50910,557 71.1%  
Interest coverage x0.271.4 0.3%   
Debt to equity ratio x0.40 30,001.3%  
Sales to assets ratio x0.50.8 61.9%   
Return on assets %0.613.1 4.8%  
Return on equity %-8.516.0 -53.0%  
Return on capital %1.623.5 6.7%  
Exports to sales %013.3 0.0%   
Imports to sales %13.93.3 414.9%   
Exports (fob) Rs mNA1,126 0.0%   
Imports (cif) Rs m517283 182.7%   
Fx inflow Rs m01,146 0.0%   
Fx outflow Rs m517355 145.4%   
Net fx Rs m-517791 -65.3%   
CASH FLOW
From Operations Rs m5141,485 34.6%  
From Investments Rs m-123-620 19.9%  
From Financial Activity Rs m-387-753 51.4%  
Net Cashflow Rs m4113 3.7%  

Share Holding

Indian Promoters % 32.9 68.9 47.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.7 3.8%  
FIIs % 0.6 7.5 7.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 19.0 349.5%  
Shareholders   20,121 23,730 84.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY19); Net Profit Up 74.5% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, FDC LTD. has posted a net profit of Rs 511 m (up 74.5% YoY). Sales on the other hand came in at Rs 3 bn (up 16.7% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - NATCO PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS